{
    "N/R/U": null,
    "Applicant": "Celgene Corporation, a Bristol-Myers Squibb Company",
    "BLA Number": "125736",
    "Proprietary Name": "Abecma",
    "Proper Name": "idecabtagene vicleucel",
    "BLA Type": "351(a)",
    "Strength": "300 to 460 X 10^6 CHIMERIC ANTIGEN RECEPTOR (CAR)-POSITIVE T CELLS",
    "Dosage Form": "Suspension",
    "Route of Administration": "Intravenous",
    "Product Presentation": "Bag",
    "Marketing Status": "Rx",
    "Licensure": "Licensed",
    "Approval Date": "March 03, 2021",
    "Ref. Product Proper Name": null,
    "Ref. Product Proprietary Name": null,
    "Supplement Number": "0",
    "Submission Type": "Original",
    "License Number": "2252",
    "Product Number": "001",
    "Center": "CBER",
    "Date of First Licensure": null,
    "Exclusivity Expiration Date": null,
    "First Interchangeable Exclusivity Exp. Date": null,
    "Ref. Product Exclusivity Exp. Date": null,
    "Orphan Exclusivity Exp. Date": "April 04, 2031"
}